Obestatin levels in response to a meal and association with subsequent appetite sensations in maintenance hemodialysis patients

What Was Tested

This observational study looks at Ghrelin.

The researchers aimed to investigate obestatin's potential role in dietary intake regulation by examining response to a meal in maintenance hemodialysis (MHD) patients.

Why It Was Studied

Obestatin, a physiological opponent of acylated ghrelin, is linked to appetite suppression regulation in mice but its anorexigenic properties in humans are controversial.

Who Took Part

The study group was 21 patients.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

In this prospective observational case series study, the researchers investigated the response of obestatin to a fixed calorie meal (500 kcal) in 21 MHD patients (age 69.2 ± 13.1 years, 10 women, with a body mass index 27.2 ± 5.5 kg/m2).

Parallel changes in serum obestatin and insulin levels and subjective scores of appetite (visual analogue scales for hunger, satiety, fullness and prospective food consumption) were recorded on fasting and 30, 60 and 120 min after the meal.

How the Study Was Run

The design is described as parallel-group.

The Ghrelin group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Appetite Regulation, Biomarkers, Ghrelin, Kidney Diseases, Postprandial Period, Renal Dialysis and Satiety Response.

The authors tagged it with the keywords Hemodialysis, Insulin sensitivity, Obestatin and Visual analogue scales (VAS) for appetite.

What This Means in Plain Language

The paper is a parallel-group study of Ghrelin in 21 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Ghrelin compound page, all human trials.